etomoxir has been researched along with bortezomib in 2 studies
Studies (etomoxir) | Trials (etomoxir) | Recent Studies (post-2010) (etomoxir) | Studies (bortezomib) | Trials (bortezomib) | Recent Studies (post-2010) (bortezomib) |
---|---|---|---|---|---|
260 | 8 | 93 | 6,868 | 860 | 4,753 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Cózar-Castellano, I; Joumady, I; Perdomo, G; Sáez-Benito, A; Tirado-Vélez, JM | 1 |
2 other study(ies) available for etomoxir and bortezomib
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Inhibition of fatty acid metabolism reduces human myeloma cells proliferation.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Boronic Acids; Bortezomib; Carbohydrate Metabolism; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cerulenin; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Epoxy Compounds; Fatty Acids; G1 Phase Cell Cycle Checkpoints; Glucose; Humans; Lactones; Lipid Metabolism; Multiple Myeloma; Orlistat; Oxidation-Reduction; Pyrazines; Retinoblastoma Protein | 2012 |